News & Media
Media
FEATURED
Learn more about our ACCUM technology
Making a Global Impact
News Releases
Defence Therapeutics Strengthens Its Scientific Advisory Board With The Appointment Of Dr. Sarkis Meterissian
Montreal, QC, Canada, May 29th, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC) a publicly traded biotechnology and precision intracellular drug-delivery company, announces that Dr. Sarkis Meterissian resigned today...
Defence Therapeutics Enhances In-House Adc Development Platform With Expanded Analytical And Cellular Testing Capabilities
Montreal, QC, Canada, May 19th, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the expansion of internal...
Defence Therapeutics Announces Grant Of Restricted Stock Units
Montreal, QC, Canada, April 24, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, wishes to announce that the board of directors of the...
Defence Therapeutics Announces Warrant Terms Amendment
Montreal, QC, Canada, March 20, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce an amendment to the terms of a...
Defence Therapeutics Announces Closing Of Private Placement Of Units For Gross Proceeds Of $9,595,000
Montreal, QC, Canada, March 9, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the closing of a private...
Defence Therapeutics To Showcase Accum® Platform At Key International Industry Events In March
Montreal, QC, Canada, March 2nd, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology company advancing next-generation therapeutics using its proprietary Accum® platform, today outlined its participation in a series of major...
Defence Therapeutics Announces Private Placement Of Units For Proceeds Of Up To $11 Million
Montreal, QC, Canada, February 27th, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a publicly traded biotechnology and precision intracellular drug-delivery company, is pleased to announce the launch of a private...
Defence Therapeutics Aligns Accum Adc Strategy Through Multidisciplinary Scientific Advisory Board
Montreal, QC, Canada, February 10th, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, reported on its Scientific Advisory Board (“SAB”) meeting held on January 30, 2026,...
Defence Therapeutics To Present At The World Adc Europe 2026 Showcasing Accum Precision Intracellular Drug-Delivery Platform
Montreal, QC, Canada, February 4th, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced that it will present at World ADC Europe 2026, taking place February...
Defence Therapeutics Expands Collaboration With Canadian Nuclear Laboratories To Accelerate Its Proprietary Radiopharmaceutical Pipeline
Montreal, QC, Canada, January 28th, 2026 — Defence Therapeutics Inc. (“Defence” or the “Company”), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced the strengthening of its long-standing collaboration with Canadian...
Defence Therapeutics Sharpens Strategic Focus On Precision Drug Delivery To Unlock The Full Potential Of Cancer Biologics
Montreal, QC, Canada, January 21st, 2026 — Defence Therapeutics Inc., (“Defence” or the “Company”), a publicly traded biotechnology company, today announced an evolution of its corporate positioning to reflect its focus as a precision intracellular drug-delivery...
Defence Therapeutics Announces Agm Results And Provides Corporate Updates
Montreal, QC, Canada, December 10th, 2025 - Defence Therapeutics Inc. (“Defence” or the “Company”), a biotechnology company advancing a proprietary intracellular delivery platform that enables more potent, safer, and more effective antibody-based and radiotherapeutic...